NEO · Neogenomics Inc
$15.94
-0.45 (-2.75%)
At close · Aug 14
Market Cap
$2.08B
Shares
130.21M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$727.33M
+10.1%
FY2025
Net Income
-$108.03M
-37.2%
FY2025
Gross Margin
43.21%
-0.7pp
FY2025
Operating Margin
-15.93%
-2pp
FY2025
Diluted EPS
-$0.04
-300%
FY2015
Operating Cash Flow
$5.23M
-25.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $745.97M | $727.33MG | $660.57MG | $591.64M | $509.73M | $484.33M | $444.45M | $408.83M | $276.74M | $240.25M | $231.81M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $5.54M | $10M | — | — | — | — | — | — | |
| $424.06M | $413.04M | $370.47M | $347.04M | $321.83M | $297.27M | $258.56M | $211.99M | $149.48M | $138.3M | $133.7M | — | — | — | — | — | — | |
| $321.91M | $314.29M | $290.1M | $244.6M | $187.9M | $187.06M | $185.89M | $196.84M | $127.27M | $101.96M | $98.1M | $43.76M | $40.71M | $31.74M | $26.84M | $19.43M | $15.78M | |
| — | 43.21% | 43.92% | 41.34% | 36.86% | 38.62% | 41.83% | 48.15% | 45.99% | 42.44% | 42.32% | — | — | — | — | — | — | |
| $36.43M | $37.08M | $31.16M | $27.31M | $30.33M | $21.87M | $8.23M | $8.49M | $3M | $3.64M | $4.65M | $4.2M | $2.69M | $2.44M | $2.28M | $543K | — | |
| $93.15M | $92.01M | $84.65M | $70.84M | $67.32M | $62.59M | $47.86M | $47.35M | $29.4M | $24M | $23.91M | $11.56M | $12M | $8.73M | $7.5M | $6.96M | $7.48M | |
| $270.87M | $273.34M | $259.74M | $243.1M | $243.36M | $221.35M | $143.79M | $127.99M | $84.82M | $70.36M | $63.93M | $33.63M | $23.81M | $17.4M | $15.84M | $12.33M | $11.27M | |
| $31.02M | $31.75M | $33.45M | $35.13M | $34.06M | $23.16M | $9.82M | $9.93M | $5.93M | $7M | $7.27M | $412K | $295K | $223K | $182K | — | — | |
| — | — | — | — | — | — | $25.9M | $20.35M | $15.8M | $15.6M | $15.94M | $6.73M | $5.35M | $4.19M | $3.64M | — | — | |
| — | $0 | $6.66M | $11.09M | $4.52M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | |
| $428.21M | $430.17M | $382.21M | $352.34M | $345.52M | $305.81M | $199.89M | $183.83M | $117.23M | $99.05M | $95.95M | $49.39M | $38.5M | $28.56M | $25.63M | $19.84M | $18.75M | |
| -$106.3M | -$115.88M | -$92.11M | -$107.74M | -$157.62M | -$118.75M | -$13.99M | $13.01M | $10.04M | $2.9M | $2.16M | -$5.64M | $2.22M | $3.17M | $1.21M | -$409K | -$2.96M | |
| — | -15.93% | -13.94% | -18.21% | -30.92% | -24.52% | -3.15% | 3.18% | 3.63% | 1.21% | 0.93% | — | — | — | — | — | — | |
| — | — | — | — | — | — | $11.91M | $33.35M | $25.84M | $18.5M | $18.09M | $1.1M | $7.56M | $7.36M | $4.85M | — | — | |
| $2.73M | $3.75M | $6.62M | $6.91M | $7.58M | $8.22M | $7.02M | $3.71M | $6.23M | $5.54M | — | $854K | $985K | $989K | $1.15M | $768K | $710K | |
| $6.62M | $9.07M | $18.43M | $16.9M | $6.08M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $219K | $296K | -$379K | $644K | -$213K | -$499K | $7.91M | -$4.63M | $14K | -$12K | $0 | $2M | -$929K | -$989K | -$1.15M | -$768K | -$340K | |
| -$102.19M | -$110.27M | -$80.68M | -$97.1M | -$159.34M | -$15.08M | -$14.06M | $3.65M | $3.82M | -$2.65M | -$7.84M | -$4.49M | $1.29M | $2.19M | $65K | -$1.18M | — | |
| -$2.98M | -$2.24M | -$1.95M | -$9.13M | -$15.09M | -$6.73M | -$18.23M | -$4.36M | $1.18M | -$2.25M | -$1.7M | -$1.95M | $157K | $152K | $0 | $0 | — | |
| -$99.21M | -$108.03M | -$78.73M | -$87.97M | -$144.25M | -$8.35M | $4.17M | $8.01M | $2.64M | -$396K | -$6.14M | -$2.54M | $1.13M | $2.03M | $65K | -$1.18M | -$3.3M | |
| — | -14.85% | -11.92% | -14.87% | -28.3% | -1.72% | 0.94% | 1.96% | 0.95% | -0.16% | -2.65% | — | — | — | — | — | — | |
| -$77.59M | — | -$78.73M | -$87.97M | -$144.25M | -$8.35M | $4.17M | $8.01M | $6.09M | -$10.94M | -$30.82M | -$2.66M | $1.13M | $2.03M | — | — | — | |
| — | -$107.82M | -$77.26M | -$85.74M | -$147.51M | -$9M | $5.8M | $6.97M | $1.79M | -$122K | -$6.14M | -$2.54M | — | — | — | — | — | |
| USD/shares | — | — | — | — | — | — | — | — | — | — | — | -$0.04 | $0.02 | $0.04 | $0.00 | -$0.03 | — |
| USD/shares | — | — | — | — | — | — | — | — | — | — | — | -$0.04 | $0.02 | $0.04 | $0.00 | -$0.03 | — |
| shares | — | 128.1M | 126.66M | 125.5M | 124.22M | 119.96M | 108.58M | 100.47M | 85.62M | 79.43M | 77.54M | 60.53M | 53.48M | 48.26M | 45.03M | 42.76M | — |
| shares | — | 128.1M | 126.66M | 125.5M | 124.22M | 119.96M | 111.79M | 103.62M | 91.57M | 79.43M | 77.54M | 60.53M | 56.02M | 52.78M | 48.72M | 42.76M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.03×
Peer median 3.82×
EV/EBIT
—
Peer median 71.18×
P/E (TTM)
—
Peer median 33.54×
Peer medians compare against the 20 similar-size Diagnostics & Research companies (of 49 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $727,332,000 | $660,566,000 | $591,643,000 | $509,728,000 | — | — | — | — |
| Advanced Diagnostics | — | — | — | — | $80,157,000 | — | — | — |
| Clinical Services | — | — | — | — | $404,172,000 | $382,337,000 | $361,161,000 | $241,873,000 |
| Pharma Services | — | — | — | — | — | $62,111,000 | $47,669,000 | $34,868,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Client Direct Billing | $518,844,000 | $475,444,000 | $428,901,000 | $370,706,000 | $252,617,000 | $240,535,000 | $212,703,000 | $164,888,000 |
| Commercial Insurance | $117,508,000 | $99,843,000 | $88,022,000 | $73,280,000 | $78,773,000 | $76,550,000 | $83,107,000 | $40,360,000 |
| Medicare and Other Governmental | $90,866,000 | $84,598,000 | $74,370,000 | $65,585,000 | $72,010,000 | — | — | — |
| Self Pay Services | $114,000 | $681,000 | $350,000 | $157,000 | $772,000 | $476,000 | $606,000 | $1,059,000 |
| Medicare and Medicaid | — | — | — | — | $72,010,000 | $64,776,000 | $64,745,000 | $35,566,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -$115,881,000 | -$92,106,000 | -$107,736,000 | -$157,623,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -15.9% | -13.9% | -18.2% | -30.9% |
Key facts
CIK
1077183
CUSIP
64049M209
13F (30d)
250 filings
248 filers
Visit website
Investor relations